Pharma's Almanac | Viral Vector Manufacturing

32 Articles Available

1 2

Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

PAO-02-23-CL-03

AAV Capsid Engineering

Expanding Patient Access to Gene Therapies through AAV Capsid Engineering

PAO-01-23-CL-02

Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

PAO-11-022-NI-09

Viral Vectors

Risk-Based Optimization of Viral Vector Processes Adds Real Value

PAO-09-022-CL-05

Cell and Gene Therapy

State of the Cell and Gene Therapy Market

PAO-10-022-NI-01

Column: M&A

Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.

PAO-06-022--NI-12

Viral Vector Manufacturing

Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months

PR-M06-22-05

Viral Vector Manufacturing

Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design

PAO-05-022-CL-02

GMP Certification

GMP Certification for Exothera Further Extends its Viral Vector Manufacturing Capacity

PR-M03-22-10

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

PAO-02-022-CL-01

Viral Vectors

Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology

PAO-02-022-CL-09

2021 Roundup: The Year of Cell and Gene Therapy

Viral Vaccines

Viral Vectors, Vaccines — A New Era Of Collaborative Design

PAO-10-21-CL-17

Cell and Gene Therapy

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

PAO-10-21-CL-12

Gene Therapy

A Customer-Centric Approach to Cell and Gene Therapy Manufacturing

PAO-10-21-CL-06

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

PAO-10-21-CL-02

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

PAO-10-21-CL-01

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

PAO-09-21-CL-14

Gene Therapy

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Cell and Gene Therapy

Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies

PAO-05-21-CL-05

Acquisition

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

PR-M11-20-035

Capacity Expansion

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

PR-M06-20-NI-029

Capacity Expansion

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

PR-M07-19-NI-043

Viral Vector Manufacturing

Accelerating The Development of Viral Vector Manufacturing Processes

PAP-Q2-2019-CL-009

1 2

Viral Vector Manufacturing

32 Articles Available

Can't find what you're looking for? Try our advanced search.

Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

AAV Capsid Engineering

Expanding Patient Access to Gene Therapies through AAV Capsid Engineering

Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

Viral Vectors

Risk-Based Optimization of Viral Vector Processes Adds Real Value

Cell and Gene Therapy

State of the Cell and Gene Therapy Market

Column: M&A

Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.

Viral Vector Manufacturing

Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months

Viral Vector Manufacturing

Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design

GMP Certification

GMP Certification for Exothera Further Extends its Viral Vector Manufacturing Capacity

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Viral Vectors

Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology

2021 Roundup: The Year of Cell and Gene Therapy

Viral Vaccines

Viral Vectors, Vaccines — A New Era Of Collaborative Design

Cell and Gene Therapy

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

Gene Therapy

A Customer-Centric Approach to Cell and Gene Therapy Manufacturing

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

Gene Therapy

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Cell and Gene Therapy

Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies

Acquisition

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Capacity Expansion

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

Capacity Expansion

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Viral Vector Manufacturing

Accelerating The Development of Viral Vector Manufacturing Processes